Arvinas gets $350M boost from investors to extend runway into 2027

Kyle LaHucik

Senior Reporter

Arvinas’ $350 million private placement will help bankroll the protein degrader biotech as it nears completion of its first Phase III study with partner Pfizer …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Arvinas gets $350M boost from investors to extend runway into 2027

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Biopharma begins to contemplate an RFK Jr.-influenced FDA if Trump wins

Pfizer shares new details on obesity pipeline, hints at ‘other opportunities’

GSK buys autoimmune T cell engager for $300M upfront from Chimagen

Novartis takes $800M MorphoSys writedown mere months after closing acquisition

Novartis highlights overall M&A track record following MorphoSys impairment

Following March inspection, Novo Nordisk's semaglutide manufacturing facility cited by FDA

Arv­inas gets $350M boost from in­vestors to ex­tend run­way in­to 2027

Senior Reporter

Sign up to read this article for free.

more like this

Viridian Therapeutics

Waltham, MA, USA

Arvinas gets $350M boost from investors to extend runway into 2027